Rockefeller Capital Management’s NovoCure NVCR Stock Holding History

Rockefeller Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.03K	Sell	200 -30,807	-99%	-$466K	﹤0.01%	4341
2026 Q1	$338K	Buy	31,007 +30,349	+4,612%	+$379K	﹤0.01%	2193
2025 Q4	$8.51K	Buy	658 +82	+14%	+$1.05K	﹤0.01%	3875
2025 Q3	$7.44K	Buy	+576	New	+$7.7K	﹤0.01%	3759
2023 Q1	–	Sell	-1,280	Closed	-$93K	–	3248
2022 Q4	$93K	Sell	1,280 -7,846	-86%	-$590K	﹤0.01%	2068
2022 Q3	$693K	Hold	9,126	–	–	﹤0.01%	1148
2022 Q2	$634K	Sell	9,126 -2,590	-22%	-$195K	﹤0.01%	1169
2022 Q1	$970K	Buy	11,716 +70	+0.6%	+$5.16K	﹤0.01%	1069
2021 Q4	$874K	Buy	11,646 +1,771	+18%	+$178K	﹤0.01%	1099
2021 Q3	$1.15M	Buy	9,875 +8,624	+689%	+$1.3M	0.01%	950
2021 Q2	$276K	Buy	1,251 +285	+30%	+$55.4K	﹤0.01%	1394
2021 Q1	$127K	Sell	966 -12	-1%	-$1.9K	﹤0.01%	1504
2020 Q4	$169K	Buy	978 +690	+240%	+$94.4K	﹤0.01%	1251
2020 Q3	$32K	Hold	288	–	–	﹤0.01%	1639
2020 Q2	$17K	Hold	288	–	–	﹤0.01%	1728
2020 Q1	$19K	Buy	+288	New	+$22.8K	﹤0.01%	1536

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Rockefeller Capital Management's NVCR Position: Q2 2026 in Review

Rockefeller Capital Management reduced its NovoCure (NVCR) stake by 99% in Q2 2026, selling an estimated $466K and leaving 200 shares worth $3.03K. The position accounts for ﹤0.01% of the portfolio, ranked #4341.

Rockefeller Capital Management first reported a position in NVCR in Q1 2020 and has held it in 16 quarters since. The position peaked at $1.15M in Q3 2021. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Rockefeller Capital Management held 200 shares of NovoCure worth $3.03K as of Q2 2026.
Rockefeller Capital Management sold 30,807 NovoCure shares in Q2 2026, an estimated $466K.
NovoCure made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4341 holding.
Rockefeller Capital Management first reported a position in NovoCure in Q1 2020 and has held it in 16 quarters since.
Rockefeller Capital Management's NovoCure position peaked at $1.15M in Q3 2021.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.